Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.58 |
| ▸ | PIK3R2 | O00459 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10146901 | 1.00 | PIK3CD (0.58) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL14827230 | 0.95 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL14827233 | 0.95 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL1695125 | 0.92 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL10146962 | 0.92 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL14815621 | 0.92 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL10147663 | 0.92 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL10146941 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL10147666 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 | |
| SCHEMBL1694830 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | PIK3CD 1181/4885PIK3CB 1532/4885PIK3CG 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.